Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRVI Trevi Therapeutics, Inc.

Pre-Mkt 04-11 05:13:06 EDT

5.28

-0.12

-2.22%

High5.32	Low4.85	Vol1.22M
Open5.30	D1 Closing5.40	Amplitude8.70%
Mkt Cap510.48M	Tradable Cap388.96M	Total Shares96.68M
T/O6.29M	T/O Rate1.65%	Tradable Shares73.67M
P/B5.12	ROE-52.59%	EPS-0.44
52wk High7.39	52wk Low2.30	P/E-11.90
Dividend0.00	Div.Yield0.00	ROA-32.15%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"TRVI","market":"US","secType":"STK","nameCN":"Trevi Therapeutics, Inc.","latestPrice":5.28,"timestamp":1744315200000,"preClose":5.4,"halted":0,"volume":1216753,"delay":0,"floatShares":73667100,"shares":96682200,"eps":-0.443732,"marketStatus":"Pre-Mkt","change":-0.12,"latestTime":"04-11 05:13:04 EDT","open":5.3,"high":5.32,"low":4.85,"amount":6290972.8038621,"amplitude":0.087037,"askPrice":5.88,"askSize":100,"bidPrice":4.43,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.443732,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744378200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1557201600000,"exchange":"NASDAQ","adjPreClose":5.28,"postHourTrading":{"tag":"盘后","latestPrice":5.02,"preClose":5.28,"latestTime":"18:41 EDT","volume":6946,"amount":36641.76,"timestamp":1744324868001},"volumeRatio":0.6882704213625819,"impliedVol":0.6078,"impliedVolPercentile":0.276},"requestUrl":"/m/hq/s/TRVI/wiki","defaultTab":"wiki","newsList":[{"id":"2525989495","title":"Trevi Therapeutics Price Target Maintained With a $24.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2525989495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525989495?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:36","pubTimestamp":1744115760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRVI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:36 ET (12:36 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TRVI"],"gpt_icon":0},{"id":"2524253267","title":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253267","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253267?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:30","pubTimestamp":1743679800,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough ,today announced that senior management will be participating in the following investor conferences in April.Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8weeks despite treatment for an underlying condition  and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-participate-upcoming-april-113000321.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-participate-upcoming-april-113000321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LENZ","TRVI","BK4139","RCC"],"gpt_icon":0},{"id":"2522626879","title":"BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2522626879","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522626879?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:47","pubTimestamp":1742989621,"startTime":"0","endTime":"0","summary":"BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The BoardMarch 26 (Reuters) - Avalo Therapeutics Inc AVTX.O:AVALO THERAPEUTICS APPOINTS MICHAEL HEFFERNAN AS CHAIRMAN OF THE BOARDAVA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA4F4LKB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COLL","BK4007","BHVN","AVTX","TRVI","BK4139","LU1093756325.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"1155783654","title":"Stock Track | Trevi Therapeutics Soars 6.40% on Strong Q4 Results and Positive Clinical Data in Chronic Cough Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1155783654","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155783654?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:32","pubTimestamp":1742391175,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics, Inc.  surged 6.40% in Wednesday's pre-market trading session following the company's release of strong fourth-quarter 2024 results and positive updates on its clinical programs for chronic cough treatments.The clinical-stage biopharmaceutical company, focused on developing treatments for chronic cough and other neurologically mediated conditions, reported encouraging progress across multiple fronts. In its earnings call, Trevi highlighted three positive data readout","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"1145823592","title":"Stock Track | Trevi Therapeutics Soars 5.18% Pre-Market on Strong Q4 Results and Positive Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1145823592","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145823592?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:28","pubTimestamp":1742390928,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics, Inc.  surged 5.18% in pre-market trading on Wednesday following the company's release of strong fourth-quarter 2024 results and positive updates on its clinical programs.The clinical-stage biopharmaceutical company, focused on developing treatments for chronic cough and other neurologically mediated conditions, reported encouraging progress across multiple fronts. In its earnings call, Trevi highlighted three positive data readouts from 2024, including the Human Abu","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Trevi Therapeutics Soars 5.18% Pre-Market on Strong Q4 Results and Positive Clinical Data","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"2520314187","title":"B.Riley Financial Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520314187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520314187?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 20:56","pubTimestamp":1742388964,"startTime":"0","endTime":"0","summary":"In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-financial-reaffirms-their-buy-rating-on-trevi-therapeutics-trvi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-financial-reaffirms-their-buy-rating-on-trevi-therapeutics-trvi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRVI"],"gpt_icon":0},{"id":"2520272907","title":"B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2520272907","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520272907?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:40","pubTimestamp":1742384423,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) has an average rating of buy and mean price target of $19.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TRVI","RILY"],"gpt_icon":0},{"id":"2520836541","title":"Q4 2024 Trevi Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520836541","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520836541?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:36","pubTimestamp":1742384174,"startTime":"0","endTime":"0","summary":"Jennifer Good; President, Chief Executive Officer, Director; Trevi Therapeutics Inc. Lisa Delfini; Chief Financial Officer; Trevi Therapeutics Inc. Good afternoon, and welcome to the Trevi Therapeutics fourth-quarter and year-end 2024 earnings conference call.  Please note, this event is being recorded.Various remarks that management makes during this conference call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent annual report on Form 10-K, which the company filed with the SEC this afternoon.In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as repre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-trevi-therapeutics-inc-113614486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","TRVI"],"gpt_icon":0},{"id":"2520020599","title":"Trevi Therapeutics Inc : Needham Cuts Target Price to $24 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2520020599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520020599?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:33","pubTimestamp":1742383985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20VY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2520059629","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520059629","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520059629?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:38","pubTimestamp":1742380720,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) today and set a price target of $15.0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-trevi-therapeutics-trvi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-trevi-therapeutics-trvi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRVI","SF"],"gpt_icon":0},{"id":"2520303229","title":"Trevi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520303229","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520303229?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 05:01","pubTimestamp":1742331664,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryTrevi Therapeutics Inc TRVI.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL8N3Q126A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI"],"gpt_icon":0},{"id":"2520934516","title":"Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward","url":"https://stock-news.laohu8.com/highlight/detail?id=2520934516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520934516?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:17","pubTimestamp":1742329020,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments.The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier.Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said.Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023.The New Haven, Conn. company did not share revenue data, in keeping with previous quarters.Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio.Trevi said it completed enrollment","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FORD","BK4007","BK4202","LENZ","TRVI","BK4139"],"gpt_icon":0},{"id":"2520931794","title":"Trevi Therapeutics: Completed Enrollment in Phase 2B Coral Trial in Ipf Patients With Chronic Cough in Feb 2025, With Topline Data Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931794?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:05","pubTimestamp":1742328305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUA962HHJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2520931791","title":"Trevi Therapeutics: Ended 2024 With $107.6 Mln in Cash, Cash Equivalents & Marketable Securities, With Expected Cash Runway Into Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931791?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:05","pubTimestamp":1742328305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUA962HHJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2520931975","title":"Trevi Therapeutics Q4 Pretax Profit USD -11.399 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931975?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:05","pubTimestamp":1742328305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLX2B0D10:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2520317569","title":"Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520317569","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520317569?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:05","pubTimestamp":1742328300,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates. Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough , making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis  and RCC. Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025. patients with RCC  in March 2025. Haduvio met the primary endpoint","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","03160","BK4585","TRVI","BK4099","BK4604","BK4555","TM","BK4007","BK4139","LENZ","BK4588"],"gpt_icon":0},{"id":"2519319332","title":"Trevi Therapeutics Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519319332","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519319332?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 04:12","pubTimestamp":1741983142,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc  expected to post a loss of12cents a share - Earnings Preview Trevi Therapeutics Inc TRVI.OQ TRVI.O is expected to show no change in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX21C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI"],"gpt_icon":0},{"id":"2518772527","title":"Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518772527","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518772527?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:05","pubTimestamp":1741723500,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 4:30 p.m. ET. NEW HAVEN, Conn., March 11, 2025 /PRNewswire/ --Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough , today announced that senior management will host a conference call and live audio webcast on Tuesday, March 18, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2024.Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8weeks despite treatment for an underlying condition  and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-report-fourth-quarter-200500840.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-report-fourth-quarter-200500840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LENZ","TRVI","BK4139","RCC"],"gpt_icon":0},{"id":"2518187726","title":"TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518187726","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518187726?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 21:56","pubTimestamp":1741701360,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment for refractory chronic cough .The study met its primary endpoint — treatment with Haduvio achieved a statistically significant reduction in the 24-hour cough frequency by 67% from baseline and 57% on a placebo-adjusted basis. Similar efficacy was also seen in Haduvio-treated patients when categorized across severity levels, with a 66% reduction in 24-hour cough frequency in patients with severe cough  and a 68% reduction in those with moderate cough . These results reinforce the drug’s potential as a broad treatment option, effectively reducing cough frequency regardless of baseline severity.Haduvio also demonstrated a strong treatment response, with 84% of patients achieving at least a 30% reduction in 24-hour cough frequency from baseline compared with 29% in the placebo group.Haduvio’s s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trvi-stock-soars-meeting-primary-135600582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","MRK","LU1291159041.SGD","CRL","LU1941712264.USD","GSK.UK","LU1989772840.SGD","LU1057294990.SGD","LU1116320901.HKD","RCC","LU2361045086.USD","LU1066051225.USD","LU2112291526.USD","BK4532","LU1989771016.USD","GSK","LU2089984988.USD","BK4530","TRVI","LU0058720904.USD","LU0006306889.USD","LU1917777945.USD","LU2023250504.SGD","SG9999015341.SGD","IE00B2B36J28.USD","LU0234572021.USD","IE00BJJMRZ35.SGD","BK4533","LU0203347892.USD","IE00BLSP4452.SGD","LU1061106388.HKD","LU2461242641.AUD","LU0320765646.SGD","BK4588","LU1035773651.USD","LU2106854487.HKD","LU0265550946.USD","IE0009355771.USD","IE00BSNM7G36.USD","LU0965509283.SGD","SG9999001176.SGD","SGXZ57979304.SGD","LU0390134368.USD","IE0002141913.USD","LU1941712348.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","LU1066051498.USD","LU1989772923.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2518057352","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Trevi Therapeutics (TRVI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518057352","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518057352?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 01:50","pubTimestamp":1741629008,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report) and Trevi The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biontech-se-bntx-and-trevi-therapeutics-trvi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biontech-se-bntx-and-trevi-therapeutics-trvi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BNTX","BK4568","BK4007","BK4548","BK4137","BK4588","TRVI","BK4551","BK4139","BK4535","HCSG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trevitherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1511},{"period":"1month","weight":-0.1619},{"period":"3month","weight":0.3822},{"period":"6month","weight":0.6923},{"period":"1year","weight":0.9341},{"period":"ytd","weight":0.2816}],"compareEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":-0.0564},{"period":"3month","weight":-0.0963},{"period":"6month","weight":-0.0949},{"period":"1year","weight":0.0203},{"period":"ytd","weight":-0.1049}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.099656},{"month":2,"riseRate":0.833333,"avgChangeRate":0.203564},{"month":3,"riseRate":0.5,"avgChangeRate":0.396594},{"month":4,"riseRate":0.333333,"avgChangeRate":0.082132},{"month":5,"riseRate":0,"avgChangeRate":-0.142766},{"month":6,"riseRate":0.833333,"avgChangeRate":0.27262},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.074501},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.08811},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.120284},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.120364},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.07561},{"month":12,"riseRate":0.666667,"avgChangeRate":0.048916}],"exchange":"NASDAQ","name":"Trevi Therapeutics, Inc.","nameEN":"Trevi Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Trevi Therapeutics, Inc.,TRVI,Trevi Therapeutics, Inc.股票,Trevi Therapeutics, Inc.股票老虎,Trevi Therapeutics, Inc.股票老虎国际,Trevi Therapeutics, Inc.行情,Trevi Therapeutics, Inc.股票行情,Trevi Therapeutics, Inc.股价,Trevi Therapeutics, Inc.股市,Trevi Therapeutics, Inc.股票价格,Trevi Therapeutics, Inc.股票交易,Trevi Therapeutics, Inc.股票购买,Trevi Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}